Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 15.08 is 13% below its 2-year average of 17.32, around the middle of its 2-year range (0.00–47.60).
As of the fiscal period ended Tuesday, June 30, 2026. 47.49% below its 12-month average of 28.72.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 15.08.
QUICK RATIO (ACID-TEST)
15.08
QUICK RATIO (ACID-TEST) AVG TTM
28.72
QUICK RATIO (ACID-TEST) AVG 3Y
N/A
QUICK RATIO (ACID-TEST) AVG 5Y
N/A
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-47.49%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 870 covered companies
CURRENT VS SECTOR MEDIAN
+349.42%
vs the sector median at left
LB Pharmaceuticals Inc Common Stock
Market Cap
$982.46M
Quick Ratio (Acid-Test)
15.08
TTM Avg
28.72
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$981.66M
Quick Ratio (Acid-Test)
3.76
TTM Avg
1.39
3Y Avg
1.76
5Y Avg
2.46
Market Cap
$978.09M
Quick Ratio (Acid-Test)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$973.93M
Quick Ratio (Acid-Test)
3.94
TTM Avg
2.64
3Y Avg
3.04
5Y Avg
2.66
Market Cap
$992.14M
Quick Ratio (Acid-Test)
19.15
TTM Avg
11.70
3Y Avg
12.62
5Y Avg
12.74
Market Cap
$996.65M
Quick Ratio (Acid-Test)
5.35
TTM Avg
6.89
3Y Avg
6.87
5Y Avg
8.97
Market Cap
$998.69M
Quick Ratio (Acid-Test)
8.42
TTM Avg
11.89
3Y Avg
15.48
5Y Avg
17.00
Market Cap
$953.81M
Quick Ratio (Acid-Test)
16.33
TTM Avg
11.68
3Y Avg
16.13
5Y Avg
16.13
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $982.46M | 15.08 | 28.72 | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $981.66M | 3.76 | 1.39 | 1.76 | 2.46 |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 3.94 | 2.64 | 3.04 | 2.66 |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | 19.15 | 11.70 | 12.62 | 12.74 |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | 5.35 | 6.89 | 6.87 | 8.97 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | 8.42 | 11.89 | 15.48 | 17.00 |
| Immatics N.V. (IMTX)vs › | $1.01B | 7.54 | 10.49 | 6.85 | 5.34 |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | 16.33 | 11.68 | 16.13 | 16.13 |
| Savara Inc. (SVRA)vs › | $952.91M | 10.13 | 12.79 | 15.72 | 14.10 |
Quick Ratio
15.08
Excludes inventory
Current Ratio
15.08
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 15.08 |
| 2026-03-31 | 35.68 |
| 2025-12-31 | 41.44 |
| 2025-09-30 | 47.60 |
| 2025-06-30 | 3.78 |
| 2025-03-31 | 3.78 |
| 2024-09-30 | 0.00 |
| 2024-06-30 | 0.00 |
| 2024-03-31 | 8.55 |
